Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Moderate Buy" by Analysts

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $60.00.

A number of analysts have recently issued reports on MNPR shares. Chardan Capital started coverage on shares of Monopar Therapeutics in a report on Monday, June 23rd. They set a "buy" rating and a $60.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Jones Trading reaffirmed a "hold" rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd. Wall Street Zen raised shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Cantor Fitzgerald started coverage on shares of Monopar Therapeutics in a report on Monday, July 7th. They set an "overweight" rating and a $74.00 price target on the stock.

Monopar Therapeutics Price Performance

NASDAQ MNPR traded down $0.77 during trading hours on Friday, reaching $46.48. 30,457 shares of the company's stock traded hands, compared to its average volume of 363,996. Monopar Therapeutics has a 52-week low of $1.72 and a 52-week high of $54.30. The firm has a market cap of $284.46 million, a PE ratio of -13.36 and a beta of 1.01. The firm has a 50-day simple moving average of $35.86 and a 200 day simple moving average of $36.31.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.27. Sell-side analysts forecast that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Christopher M. Starr sold 16,800 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the transaction, the director owned 5,173 shares of the company's stock, valued at approximately $206,920. This trade represents a 76.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the sale, the director owned 11,486 shares in the company, valued at approximately $459,440. The trade was a 43.67% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,504 shares of company stock valued at $1,700,160. 20.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Monopar Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. AlphaQuest LLC bought a new stake in shares of Monopar Therapeutics during the first quarter valued at approximately $44,000. JPMorgan Chase & Co. bought a new stake in shares of Monopar Therapeutics during the fourth quarter valued at approximately $45,000. Gerber LLC bought a new stake in shares of Monopar Therapeutics during the first quarter valued at approximately $204,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Monopar Therapeutics during the first quarter valued at approximately $328,000. Finally, Jane Street Group LLC bought a new stake in shares of Monopar Therapeutics during the first quarter valued at approximately $377,000. Institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.